Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

333P - Identification of translational renal cell carcinomas based on transformer model and pathogenomic data: A multicenter study

Date

07 Dec 2024

Session

Poster Display session

Presenters

Dingwei Ye

Citation

Annals of Oncology (2024) 35 (suppl_4): S1505-S1530. 10.1016/annonc/annonc1689

Authors

D. Ye, X. Tian, S. Zhu, H. Zhang

Author affiliations

  • Urology, Fudan University Shanghai Cancer Center, 200032 - Shanghai/CN

Resources

This content is available to ESMO members and event participants.

Abstract 333P

Background

Translational Renal Cell Carcinoma (TRCC) is a rare subtype of renal cell carcinoma that often mimics the pathological morphology of clear cell renal cell carcinoma (ccRCC) and papillary renal cell carcinoma. Historically, distinguishing TRCC from these subtypes using hematoxylin and eosin (HE) stained morphology has been challenging. The advent of large-scale deep learning models now offers a promising solution to this issue.

Methods

This study involved a retrospective screening of approximately 8,000 renal cell carcinoma cases from three medical centers, including 80 TRCC and 80 ccRCC cases represented in HE stained slide scans. After cropping images, segmenting into patches, removing blank images, and standardizing color, the data was divided into a training set (n=100) and a validation set (n=60). A Transformer model was employed for training and feature extraction. Subsequently, a machine learning model capable of distinguishing TRCC from ccRCC was developed using the features derived from the Transformer model, employing algorithms such as ExtraTrees, Random Forests, KNN, XGBoost, and LightGBM.

Results

The processing of approximately 1.5 million patch patterns from the pathological images enabled significant differentiation between TRCC and ccRCC based on Transformer-derived features. The area under the curve (AUC) for the training set reached 0.932, while the validation set achieved an AUC of 0.869. Among the machine learning models tested, the ExtraTrees model, when integrated with Transformer model features, demonstrated superior performance in accurately identifying TRCC.

Conclusions

This multicenter study successfully developed and validated a deep learning-based model for the identification of TRCC using pathological omics data. The findings highlight the potential of integrating advanced machine learning techniques with traditional pathological analysis to enhance diagnostic accuracy for rare cancer subtypes.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.